BioVie Inc Ordinary Shares - Class A BIVI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
New to The Street Show 775 Premieres Tonight on Bloomberg Television Across the United States, Latin America, MENA and Southeast Asia, Featuring American Fusion, HPB, T-REX Acquisition Corp. and SyncMeOn
-
New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global
-
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
-
Alliance Entertainment and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
-
Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results
-
New to The Street Broadcasts Today Across Bloomberg Television U.S., Latin America and MENA at 6:30 PM ET
-
First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
-
New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results
Trading Information
- Previous Close Price
- $1.28
- Day Range
- $1.28–1.40
- 52-Week Range
- $0.82–3.79
- Bid/Ask
- $1.35 / $1.38
- Shares Outstanding
- 8.68M
- Market Cap
- $12.07M
- Volume/Avg
- 204,863 / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
- Website
- https://www.bioviepharma.com
Valuation
|
Metric
|
BIVI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.02 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BIVI
|
|---|---|
Quick Ratio | 2.93 |
Current Ratio | 3.59 |
Interest Coverage | −1,265.39 |
Quick Ratio
BIVI
Profitability
|
Metric
|
BIVI
|
|---|---|
Return on Assets (Normalized) | −93.52% |
Return on Equity (Normalized) | −107.77% |
Return on Invested Capital (Normalized) | −109.10% |
Return on Assets
BIVI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#x$$YTB | LOCK|#>@N^ | $129B | |||
| Moderna Inc
MRNA
| LOCK|!q$FK& | LOCK|$&> | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#yzYZyp | LOCK|<Y># | $77B | |||
| argenx SE ADR
ARGX
| LOCK|TbTFKV | LOCK|v#P | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?%S?>c | LOCK|&$> | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|X%?#h&& | LOCK|zB<!? | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$!&nJfq | LOCK|Z!??p | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|&d>#QJ | LOCK|%%! | $24B | |||
| Incyte Corp
INCY
| LOCK|<#wSTPm | LOCK|Dl | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|!?^y%!@ | LOCK|Gp | $14B |
United States